← Back to Search

Cannabinoid

THC for Cannabis Effects (THC-Gender Trial)

Phase 1
Recruiting
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Taking estrogen supplements or oral contraceptive pills (for women)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 minutes after thc infusion begins

Summary

This trial will study how men and women differ in their reaction to marijuana.

Who is the study for?
This trial is for people who have tried cannabis at least once and are in good physical and mental health. Women can't join if they're taking estrogen supplements or birth control pills, and it's not for anyone who has never used cannabis or those dealing with major stress recently.
What is being tested?
The study is looking into how THC (the active component of cannabis) affects men and women differently when taken acutely. Participants will receive either THC or a placebo to compare the immediate effects between genders.
What are the potential side effects?
THC may cause short-term side effects such as altered senses, changes in mood, impaired body movement, difficulty with thinking and problem-solving, impaired memory, hallucinations, delusions, or psychosis.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking estrogen supplements or oral contraceptive pills.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 minutes after thc infusion begins
This trial's timeline: 3 weeks for screening, Varies for treatment, and 25 minutes after thc infusion begins for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rewarding Effects measured by Visual Analog Scale (VAS)
Verbal Learning: measured by Rey Auditory Verbal Learning Test (AVLT)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: THCActive Control1 Intervention
Active THC (0.015mg/kg) administered intravenously over 10 minutes.
Group II: PlaceboPlacebo Group1 Intervention
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,924 Previous Clinical Trials
3,031,558 Total Patients Enrolled
14 Trials studying Cannabis
724 Patients Enrolled for Cannabis

Media Library

THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT02781519 — Phase 1
Cannabis Research Study Groups: THC, Placebo
Cannabis Clinical Trial 2023: THC Highlights & Side Effects. Trial Name: NCT02781519 — Phase 1
THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02781519 — Phase 1
~5 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top